Genomic and virulence analysis of in vitro cultured Cryptosporidium parvum

Nigel Yarlett1,2, Mary Morada2, Deborah A Schaefer3

  • 1Department of Chemistry and Physical Sciences, Pace University, New York, New York, United States of America.

Plos Pathogens
|February 28, 2024
PubMed

Insights

Long-term in vitro cultivation of Cryptosporidium parvum in hollow fiber bioreactors (HFB) maintains parasite virulence and genome stability. Oocysts produced in vitro are as infectious as those from animal models, enabling non-animal production for clinical trials.

Area of Science:

  • Parasitology
  • Infectious Diseases
  • Biotechnology

Background:

  • Cryptosporidium parvum is a significant cause of diarrheal disease.
  • In vitro cultivation methods are crucial for studying parasite biology and developing interventions.
  • Hollow Fiber Bioreactor (HFB) technology allows continuous cultivation of parasites through all life cycle stages.

Purpose of the Study:

  • To evaluate the impact of long-term (over 20 months) in vitro culture on Cryptosporidium parvum.
  • To assess changes in virulence factors, genome conservation, and pathogenicity of in vitro-cultured parasites.
  • To validate the use of HFB-derived oocysts for non-animal production in clinical research.

Main Methods:

  • Long-term in vitro culture of Cryptosporidium parvum using HFB technology.
  • Analysis of sequence variation to assess genome conservation.
  • In vivo calf model infections to evaluate pathogenicity and oocyst shedding.

Main Results:

  • Low-level sequence variation was observed, comparable to parasites passaged in vivo.
  • HFB-cultured oocysts induced diarrhea in calves with similar volume, duration, and oocyst shedding intensity as in vivo passaged parasites.
  • The study demonstrates the feasibility of producing sufficient quantities of infectious oocysts for clinical trials without animal use.

Conclusions:

  • Long-term in vitro cultivation of Cryptosporidium parvum using HFB technology preserves its virulence and genetic integrity.
  • HFB technology offers a viable alternative for producing infectious oocysts for research and clinical applications.
  • This advancement facilitates non-animal production of Cryptosporidium parvum oocysts, supporting ethical research and development of treatments.